TY - JOUR
T1 - Negative Cardiovascular Consequences of Small Molecule Immunosuppressants
AU - Chakkera, H. A.
AU - Sharif, A.
AU - Kaplan, B.
N1 - Publisher Copyright:
© 2017 American Society for Clinical Pharmacology and Therapeutics
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Immunosuppressants are critical after transplantation and prescribed as immune-modulators for autoimmune disorders and glomerulonephritides. Immunosuppressants include large (e.g., thymoglobulin, alemtuzumab, and rituximab) and small molecules (e.g., corticosteroids, calcineurin inhibitors, antimetabolites, and mammalian target of rapamycin (mTOR) inhibitors). The majority of the small molecules worsen traditional cardiovascular risks. This review describes cardiovascular risks of small molecule immunosuppressants: corticosteroids, calcineurin inhibitors (tacrolimus and cyclosporine), and mTOR inhibitors (rapamycin), by categorizing these risks into two categories: ischemic heart disease and nonischemic cardiac effects.
AB - Immunosuppressants are critical after transplantation and prescribed as immune-modulators for autoimmune disorders and glomerulonephritides. Immunosuppressants include large (e.g., thymoglobulin, alemtuzumab, and rituximab) and small molecules (e.g., corticosteroids, calcineurin inhibitors, antimetabolites, and mammalian target of rapamycin (mTOR) inhibitors). The majority of the small molecules worsen traditional cardiovascular risks. This review describes cardiovascular risks of small molecule immunosuppressants: corticosteroids, calcineurin inhibitors (tacrolimus and cyclosporine), and mTOR inhibitors (rapamycin), by categorizing these risks into two categories: ischemic heart disease and nonischemic cardiac effects.
UR - http://www.scopus.com/inward/record.url?scp=85024397028&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85024397028&partnerID=8YFLogxK
U2 - 10.1002/cpt.738
DO - 10.1002/cpt.738
M3 - Review article
C2 - 28512771
AN - SCOPUS:85024397028
SN - 0009-9236
VL - 102
SP - 269
EP - 276
JO - Clinical pharmacology and therapeutics
JF - Clinical pharmacology and therapeutics
IS - 2
ER -